David Zaccardelli
CIK 1627642 · President and CEO · last filed 2026-07-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VRNA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 272
LINCOLNSHIRE, IL 60069
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VOR | Director | — | $18.33 | — | $0 | 1 | 2026-07-09 |
| SABSW | Director | — | $0.00 | — | $0 | 1 | 2026-01-07 |
| Verona Pharma plc (VRNA) Delisted | President and CEO | 3,285,280 | $106.91 | $351.23M | -$35.28M | 43 | 2025-10-08 |
| Dova Pharmaceuticals Inc. (DOVA) Delisted | President & CEO | 0 | — | — | -$253.1K | 4 | 2019-11-12 |
| MELINTA THERAPEUTICS, INC. /NEW/ (MLNT) Delisted | Director | 9,300 | — | — | $200.0K | 3 | 2019-06-12 |
| MELINTA THERAPEUTICS, INC. /NEW/ (CEMP) Delisted | Acting Chief Executive Officer | — | — | — | $0 | 2 | 2016-12-13 |
| UTHR | EVP & Chief Operating Officer | 1,542 | $592.84 | $914.2K | -$10.29M | 50 | 2016-05-16 |
Recent Filings · Page 2 of 12
111 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-05-05 | Verona Pharma plc (VRNA) Delisted | Mixed | −387,008 | -$5.31M | EDGAR |
| 2025-05-02 | — | Notice (144) | −50,000 | -$3.61M | EDGAR |
| 2025-05-01 | Verona Pharma plc (VRNA) Delisted | Mixed | +139,152 | -$811.4K | EDGAR |
| 2025-02-04 | Verona Pharma plc (VRNA) Delisted | Mixed | +33,272 | -$1.19M | EDGAR |
| 2024-12-06 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −870,672 | -$4.36M | EDGAR |
| 2024-12-02 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −125,328 | -$627.2K | EDGAR |
| 2024-11-26 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −1,600 | -$8.0K | EDGAR |
| 2024-11-13 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −2,400 | -$12.0K | EDGAR |
| 2024-11-12 | — | Notice (144) | −125,000 | -$4.82M | EDGAR |
| 2024-11-05 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −141,032 | -$618.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.